Shedding New Light on Kinase Biochemistry through Physical Simulation and Machine Learning
Wafik S. El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center, shared a post on LinkedIn:
“Outstanding presentation by Dr. Brenda Rubenstein at the Cancer Biology Program meeting at Legorreta Cancer Center, Brown U Cancer, The Warren Alpert Medical School of Brown University, Brown University, Robert W. Sobol Junior, Patrycja Dubielecka, Jeremy Warner and John Reagan.
She discussed machine learning approaches and use of dynamic simulations to understand cancer-drug target interactions and resistance mechanisms using Abl kinase as a model.”
Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.
More posts featuring Wafik S. El-Deiry.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023